

# Off-label use of reduced dose direct oral factor Xa inhibitors in subjects with atrial fibrillation: a review of clinical evidence

Mario Bo <sup>1\*</sup>, Alberto Corsini <sup>2,3</sup>, Enrico Brunetti <sup>1</sup>, Gianluca Isaia<sup>1</sup>, Maddalena Gibello<sup>1</sup>, Nicola Ferri <sup>4</sup>, Daniela Poli<sup>5</sup>, Niccolò Marchionni <sup>6</sup>, and Gaetano Maria De Ferrari <sup>7</sup>

<sup>1</sup>Section of Geriatrics, Department of Medical Sciences, Università di Torino, A.O.U. Città della Salute e della Scienza, Molinette, Corso Bramante 88, 10126 Turin, Italy; <sup>2</sup>Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Via Giuseppe Balzaretti 9, 20133 Milan, Italy; <sup>3</sup>IRCCS Multimedica Hospital, Via Gaudenzio Fantoli 16/15, 20138 Milan, Italy; <sup>4</sup>Department of Pharmaceutical and Pharmacological Sciences, Università degli Studi di Padova, Via Marzolo 5, 35131 Padua, Italy; <sup>5</sup>Centro Trombosi, Cardiothoracovascular Department, A.O.U. Careggi, Largo Brambilla 3, 50134 Florence, Italy; <sup>6</sup>Division of General Cardiology, Cardiothoracovascular Department, Department of Clinical and Experimental Medicine, A.O.U. Careggi, University of Florence, Largo Brambilla 3, 50134 Florence, Italy; and <sup>7</sup>Division of Cardiology, Department of Medical Sciences, Università di Torino, A.O.U. Città della Salute e della Scienza, Molinette, Corso Bramante 88, 10126 Turin, Italy

Received 1 June 2020; revised 31 July 2020; editorial decision; editorial decision 20 August 2020; accepted 20 August 2020; online publish-ahead-of-print 27 August 2020

In real-world clinical practice, underdosing, i.e. off-label use of reduced doses (RDs), of oral factor Xa inhibitors (oFXals) is quite common in stroke prevention in non-valvular atrial fibrillation, possibly reflecting the hope to increase safety without reducing efficacy in selected patients. To assess whether this strategy is associated with some clinical benefit, we used a physician-centred approach to evaluate whether current evidence supports the hypothesis that a substantial proportion of underdosing may be voluntary rather than casual, whether and to what extent oFXals' dose rather than patients' characteristics are associated with bleeding events, and which are the safety and efficacy clinical implications of oFXals' underdosing. Our review found consistent evidence that underdosing is often an intentional strategy; however, available studies do not demonstrate a sizeable net clinical benefit of using off-label RD oFXals.

## Keywords

Non-valvular atrial fibrillation • Direct oral anticoagulants • Oral anticoagulant therapy • Underdosing • Off-label dosing • Reduced doses

## Introduction and scope of the review

Since the net clinical benefit of direct oral anticoagulants (DOACs) over warfarin has been demonstrated in randomized clinical trials (RCTs),<sup>1–4</sup> DOACs have become the recommended first-line therapy for stroke prevention in non-valvular atrial fibrillation (NVAF). These medications are fixed-dose oral regimens available in two different dose options, which have been variously named (standard, full or higher dose, and reduced or lower dose); anyway, dose prescription should be in keeping with drug-specific dosing guidelines.<sup>5–7</sup> The criteria for posology adjustment and approved doses of oral factor Xa inhibitors (oFXals) for stroke prevention in NVAF according to the European Medicines Agency summary of product characteristics (SmPC) are available in [Supplementary material online, Tables S1 and S2](#), respectively. Use of reduced dose (RD) DOACs is primarily

recommended along the published European guidelines dose reduction criteria.<sup>7</sup>

In this regard, however, the differences in the RCTs' design may help to clarify the question of appropriate or inappropriate use of DOAC doses and to uniform the terminology. In the RE-LY trial, patients were randomly assigned to receive dabigatran at a dose of 150 mg or 110 mg twice daily (b.i.d.), both showing consistent efficacy and safety across a wide range of NVAF patients, with an increasing net clinical benefit when prescribed according to European recommendations.<sup>1,7–10</sup> Being independent from any patient's characteristics, the selection of the lower dabigatran dose is entirely at the physician's discretion, mainly based on patient's age, renal function, and concomitant drug therapies, and should not be regarded as inappropriate.<sup>7</sup> On the other hand, in RCTs investigating the non-inferiority of oFXals over warfarin, patients received full dose (FD) or RD of the experimental drug according to

\* Corresponding author. Tel: +39 0116336734, Fax: +39 0116961045, Email: [mario.bo@unito.it](mailto:mario.bo@unito.it)

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: [journals.permissions@oup.com](mailto:journals.permissions@oup.com).

predefined criteria.<sup>2-4</sup> In the ENGAGE AF-TIMI 48 study, higher dose (HDE) and lower dose edoxaban (LDE) once daily (o.d.) regimens have been evaluated, each including an RD according to pre-specified criteria (60/30 mg o.d.—HDE and 30/15 mg o.d.—LDE).<sup>4</sup> In the LDE group, it has been observed a 41% higher ischaemic stroke risk compared with warfarin, leading to the non-approval of this dosing regimen. Therefore, prospective RCTs data for lower doses only exist for dabigatran (110 mg b.i.d.) and edoxaban (30/15 mg o.d., but not approved).<sup>7</sup> In contrast, no lower dose group was studied for rivaroxaban in the ROCKET AF trial<sup>2</sup> and for apixaban in the ARISTOTLE trial,<sup>3</sup> but eligibility for the RD arm was predefined according to the patient's characteristics; as such, no clinical outcome data on hard endpoints are available for the use of these doses outside the tested dose reduction algorithms.<sup>7</sup> Therefore, the issue of inappropriate (or off-label) use of RD DOACs in patients not meeting the criteria for dose reduction (i.e. underdosing) mainly concerns oFXals and is by far more common than inappropriate use of FD in patients who qualify for RD (i.e. overdosing).<sup>11-50</sup> Undoubtedly, some underdosing may be ascribed to involuntary errors or to physiological fluctuations of creatinine clearance (CrCl) around the dose-reduction level, but a substantial proportion of it might reflect an intentional 'cautious' approach to DOAC use in selected patients, implying high hopes that underdosing may lessen the risk of bleeding without reducing the efficacy in stroke prevention. In fact, some uncertainties in dose selection may arise when considering that the latest European recommendations for practical use of DOACs suggest to consider the use of an RD in the presence of two or more factors including, among others, age over 75 years, previous bleeding, frailty, and high fall risk.<sup>7</sup> This may appear somehow counterintuitive since the risk of thromboembolic events has been demonstrated to further increase in very advanced age<sup>51</sup> and age over 75 years is the most powerful risk factor for stroke in NVAF patients.<sup>52</sup> Moreover, frail older patients with NVAF are less likely to receive an appropriate oral anticoagulant therapy (OAT) and, at the same time, are at greater risk of embolic stroke and death.<sup>53,54</sup> It has been well demonstrated that patients on OAT at high risk of falls have not a significantly increased risk of major bleeding (MB),<sup>54</sup> and current recommendations do not require fall risk estimation in OAT candidates.<sup>7</sup> The lack of evidence to guide optimal care for older patients with NVAF and frailty might in part explain the gap between current recommendations not to undertreat frail older patients<sup>55</sup> and the high prevalence of underdosing in real-life patients.<sup>53,54</sup>

In order to assess whether there is some evidence of a potential clinical benefit for oFXals' underdosing, we will use a physician-centred approach to evaluate current literature for the presence of (i) evidence supporting the hypothesis that a substantial proportion of underdosing may be voluntary rather than casual; (ii) a possible association of oFXals' dose with bleeding events, and its extent; and (iii) data on the safety and efficacy clinical implications of oFXals' underdosing. We will not discuss DOAC dose adjustment strategies according to plasma concentration because, despite some potential benefit has been observed in small studies,<sup>56-59</sup> there is no evidence from large RCTs that this strategy may be associated with a higher clinical benefit compared with current practice.<sup>7</sup>

## Methods

The medical literature was systematically searched through PubMed (MEDLINE) and Embase using a combination of Medical Subject Heading (MeSH) terms and keywords relevant for the treatment and conditions of interest for primary studies and systematic reviews. Search was limited to studies published in English language, between January 2010 and May 2020. Predefined exclusion criteria included: basic science and animal studies, studies focusing on different drug molecules (e.g. ximelagatran, anticoagulation reversal agents including idarucizumab), on specific non-relevant conditions [e.g. NVAF ablation, periprocedural OAT, end-stage chronic kidney disease (CKD) and haemodialysis], on outcomes not relevant for the purpose of this review (e.g. cost-effectiveness, medication adherence, quality of life), wrong publication types (e.g. case reports, abstracts and oral communications), and studies with unclear underdosing definitions. Additional relevant studies were included from the bibliographies of existing reviews and meta-analyses. The full search strings are available in [Supplementary material online](#).

## Results

### Underdosing of oral factor Xa inhibitors in real-life clinical practice

In real-life, patients with NVAF are older, more frequently of female gender, and show a high prevalence of comorbidities, polypharmacy and functional and/or cognitive impairment,<sup>54</sup> with a high prevalence of RD use,<sup>11-50,54,60</sup> particularly for apixaban. A descriptive summary of the systematically identified studies which investigated the prevalence of and the variables associated with off-label use of oFXal RDs is available in [Supplementary material online, Table S3](#). In the ORBIT-AF II study, underdosing was associated with older age, female gender, and higher embolic and bleeding risk scales,<sup>13</sup> as well as with non-White ethnicity.<sup>61</sup> Direct oral anticoagulant underdosing in 6658 Canadian primary care patients (7.2%) was associated with female gender, presence of multiple comorbidities (particularly heart failure and dementia), and concomitant therapy with aspirin and non-steroidal anti-inflammatory drugs (NSAIDs).<sup>17</sup> Among 460 older outpatients, underdosing (18%) was associated with older age, higher embolic risk score, previous MB, and history of CKD.<sup>18</sup> In a sample of 772 hospitalized patients, factors associated with inappropriate DOAC prescribing (mainly represented by underdosing, 17.4% in the overall sample) were, among others, age  $\geq 80$  years, apixaban prescription, and moderate CKD.<sup>24</sup> In a large sample of 8425 newly prescribed NVAF patients, underdosing (39%) was associated at univariate analysis with several variables, including, among others, female gender, advanced age, lower body mass index, history of CKD, lower CrCl, greater comorbidity burden, higher embolic risk score, and concomitant use of antiplatelet drugs.<sup>30</sup> Among others, age over 80 years alone, history of bleeding or high perceived bleeding risk have been reported as reasons for persistent apixaban underdosing (16.6%).<sup>15</sup> In a recent French study on 2027 NVAF patients, apixaban underdosing (18.1%) was more frequent with advancing age, despite normal renal function and body weight (BW).<sup>32</sup> Among 30 467 outpatients with NVAF from UK primary care, underdosing was observed in 21.6% and 9.1% of patients that initiated treatment with apixaban and rivaroxaban, respectively, with increasing use of RD

along with lower CrCl.<sup>33</sup> Of note, 26.9% of apixaban-underdosed patients met none dose reduction criteria.<sup>33</sup> In a recent systematic review, Santos *et al.*<sup>14</sup> reported data from 75 studies and showed that a substantial proportion of patients (25–50%) received off-label DOACs doses.

In conclusion, in real-life clinical practice, underdosing is quite common, particularly for apixaban. Several conditions, including advanced age, female gender, higher embolic and bleeding risk scores, history of bleeding and/or perceived high risk of bleeding, history of CKD, concomitant use of antiplatelet drugs or NSAIDs, have been consistently reported to be associated with underdosing, supporting the hypothesis that a substantial proportion of off-label RD oFXals' prescriptions may be voluntary rather than casual.<sup>11,13–50,62</sup>

## Oral factor Xa inhibitors' dose, patients' characteristics and bleeding events

In the ROCKET AF study, patients who experienced a gastrointestinal bleeding (GIB) were older and less often female.<sup>2</sup> Gastrointestinal bleeding occurred in the upper gastrointestinal (GI) tract (48%), lower GI tract (23%), and rectum (29%), without differences between treatment arms.<sup>2,63</sup> Rivaroxaban-treated patients with MB were more likely to be older, have a history of chronic obstructive pulmonary disease or GIB, prior use of aspirin, mild anaemia, and diastolic blood pressure  $\geq 90$  mmHg.<sup>64</sup> Compared with FD-treated patients, those treated with RD rivaroxaban (20.7%) were older, more frequently of female gender, with a greater comorbidity burden and higher stroke risk.<sup>2,65</sup> The primary safety endpoint (MB and clinically relevant non-major bleeding, CRNMB) occurred more frequently in those treated with RD rivaroxaban than in those treated with FD rivaroxaban.<sup>65</sup> Rates per year of stroke and systemic embolism (SE), GIB, haemorrhagic stroke, intracranial haemorrhage, and fatal bleeding were consistently higher among patients eligible for RD, irrespective of treatment allocation.<sup>65,66</sup>

In the overall sample of the ARISTOTLE study, the incidence of MB, which was lower in the apixaban group,<sup>3</sup> increased with advancing age (75 years or older), this latter being independently associated with an increased risk of bleeding, along with history of haemorrhage, stroke or transient ischaemic attack (TIA), concomitant use of antiplatelet drugs or NSAIDs, diabetes, lower CrCl, and anaemia prior to treatment.<sup>67</sup> Patients eligible for apixaban RD were older and at increased risk of stroke, MB, and all-cause death compared with the subjects on FD.<sup>66,67</sup> However, the effect of properly used RD apixaban vs. warfarin in these patients was consistent with that of the FD in reducing stroke, MB, and all-cause mortality.<sup>68,69</sup> Patients with only one dose reduction criterion and appropriately treated with FD apixaban did not show differences in the efficacy and safety outcomes compared with FD-treated patients who did not fulfil any dose reduction criteria.<sup>70</sup> In patients with prior GIB (who were at increased risk of recurrent major GIB) treated with an appropriate apixaban dose, efficacy and safety were consistent with the results of the overall trial.<sup>71</sup> The use of NSAIDs was associated with incident MB and CRNMB, but not with GIB.<sup>72</sup>

In the AVERROES trial, the rate of bleeding events was 3.8%/year and 4.5%/year with aspirin and apixaban, respectively.<sup>73</sup> The anatomic site of bleeding did not differ between therapies, and higher embolic risk scores were associated with increasing risk of both bleeding and

stroke.<sup>73</sup> Rates of MB on apixaban were similar to those of aspirin across all age groups, and increased with age, with absolute rates of 2.6%/year and 2.2%/year, respectively, in patients 75 years and older, compared with 0.8%/year and 0.7%/year, respectively, in patients under 75 years, with no significant treatment-by-age interaction.<sup>74</sup> Moreover, the risk of MB in patients 85 years and older was similar on apixaban and aspirin (4.7%/year and 4.9%/year).<sup>74</sup>

In the ENGAGE AF-TIMI 48 trial, the annualized rate of MB was significantly reduced in patients treated with HDE (2.75%) and with LDE (1.61%) compared with warfarin (3.43%), whereas the risk of major GIB was higher with HDE, but lower with LDE.<sup>4</sup> In the overall sample of patients, several variables were associated with an increased risk of major GIB, including older age, male gender, comorbidities (particularly heart failure, diabetes and CKD), and concomitant use of aspirin or other antiplatelet agents, and of proton pump inhibitors (PPIs) or other gastro-protective agents.<sup>75</sup> Patients who met criteria for dose reduction at randomization had a higher risk of stroke, bleeding and death compared with those who did not fulfil dose-reduction criteria.<sup>66,76</sup>

These data from RCTs demonstrate that several patients' characteristics (including older age, greater comorbidity burden, CKD, previous bleeding events, use of NSAIDs, and antiplatelet drugs), rather than oFXals' dose, are significantly and consistently associated with an increased occurrence of MB in oFXal-treated patients. Rates of MB were consistently higher among RD-treated than in FD-treated patients.<sup>66</sup> However, appropriately dose-adjusted oFXals showed an improved benefit-harm profile compared with warfarin and with aspirin.<sup>66,73</sup> Of note, in elderly patients rates of MB were similar on apixaban and on aspirin in the unique study comparing a DOAC with aspirin.<sup>74</sup>

Real-life studies demonstrated that in OAT-treated patients most MBs occur in subjects with underlying GI pathology (colonic diverticula, angiodysplasia, peptic ulcer disease, arteriovenous malformations, inflammatory bowel disease, haemorrhoids, and malignancy).<sup>77,78</sup> Older age is associated with an increased prevalence of these underlying conditions, predisposing to bleeding, and this risk is further increased in patients on OAT<sup>2,64,65,67,73–75,79,80</sup> as well as in patients on antiplatelet therapy.<sup>73,74,81</sup> There is scant evidence that OAT intensity is associated with increased bleeding risk, but strong evidence that concomitant drug therapies, including gastrotoxic drugs, single or dual antiplatelet therapy, and therapies with the potential for drug-drug interactions may substantially increase the risk of bleeding,<sup>82–84</sup> whereas the incidence of hospitalization for upper GIB was lower among DOAC-treated patients receiving concomitant PPI therapy.<sup>85</sup>

## Clinical implications of oral factor Xa inhibitors' underdosing on safety and efficacy outcomes

Since in Phase III RCTs patients received oFXals at appropriate doses, with a better benefit-harm profile compared with subjects on warfarin, evidence about clinical implications of oFXals' underdosing may be inferred only from observational real-life studies. In this context, except minor differences regarding renal function estimation formulas, consideration of potential drug–drug interactions and country-specific rivaroxaban dose differences, underdosing has been almost

**Table 1** Clinical outcomes associated with off-label reduced dose oral factor Xa inhibitors in relevant clinical studies

Study	Setting, population and definition of off-label RD oFXals' use	Incidence rate/proportion (absolute number) of selected clinical outcomes (unadjusted)	Clinical outcomes associated with off-label RD oFXals use
Steinberg et al., 2016 <sup>13</sup>	USA: 5738 NVAF outpatients on DOAC (median age 71 years, 41.8% female), 9.4% under-dosed (RD use not consistent with FDA SmPC) 3078 RI, 2235 AP, 425 DA Median follow-up: 0.99 years	Ischaemic stroke/SE/TIA: 1.32% ( <i>n</i> = 70) on-label dose DOACs, 1.95% ( <i>n</i> = 11) off-label RD DOACs MB: 3.59% ( <i>n</i> = 187) on-label dose DOACs, 4.12% ( <i>n</i> = 23) off-label RD DOACs MI: 0.77% ( <i>n</i> = 41) on-label dose DOACs, 1.06% ( <i>n</i> = 6) off-label RD DOACs All hospitalization: 42.77% ( <i>n</i> = 1727) on-label dose DOACs, 48.56% ( <i>n</i> = 212) off-label RD DOACs CV hospitalization: 24.16% ( <i>n</i> = 1093) on-label dose DOACs, 26.11% ( <i>n</i> = 129) off-label RD DOACs Bleeding hospitalization: 2.91% ( <i>n</i> = 152) on-label dose DOACs, 4.12% ( <i>n</i> = 23) off-label RD DOACs All-cause mortality: 2.95% ( <i>n</i> = 158) on-label dose DOACs, 6.30% ( <i>n</i> = 36) off-label RD DOACs	Increased CV hospitalization (aHR 1.26; 95% CI 1.07–1.50). Non-significant differences in ischaemic stroke/SE/TIA, MI, MB.
Yao et al., 2017 <sup>22</sup>	USA: 13 392 NVAF patients on DOAC with no renal indication for RD (median age 70 years, 41.8% female). 3340 AP, 5399 RI, 4653 DA Off-label RD (RD use in the absence of a renal indication): 13.3% (AP 16.5%, RI 15.1%, DA 8.9%) Median follow-up: 4.0 months	Ischaemic stroke/SE: 1.43%/year ( <i>n</i> = 14) on-label FD DOACs, 1.70%/year ( <i>n</i> = 16) off-label RD DOACs MB: 5.03%/year ( <i>n</i> = 49) on-label FD DOACs, 5.43%/year ( <i>n</i> = 51) off-label RD DOACs	Off-label RD vs. on-label FD AP associated with higher stroke risk (HR 4.87; 95% CI 1.30–18.26), but similar MB risk (HR 1.29; 95% CI 0.48–3.42). No differences in stroke or MB risk between off-label RD and on-label FD RI.
Sato et al., 2018 <sup>25</sup>	Japan: 2272 NVAF patients on DOAC (mean age 72 years, 37% female), 498 RI <sup>a</sup> , 1014 AP, 267 ED, 493 DA Off-label RD (RD use not consistent with Japan SmPC <sup>b</sup> ): 21.6% ( <i>n</i> = 490); RI 23.9%, AP 22.5%, ED 12.4%, DA 20.7% Follow-up: up to 2 years	Stroke/SE: 2.2%/year on-label dose DOACs, 2.4%/year off-label RD DOACs MB: 2.0%/year on-label dose DOACs, 2.4%/year off-label RD DOACs GIB: 1.1%/year on-label dose DOACs, 1.0%/year off-label RD DOACs ICH: 0.3%/year on-label dose DOACs, 1.2%/year off-label RD DOACs All-cause mortality: 2.3%/year on-label dose DOACs, 2.6%/year off-label RD DOACs	No significant differences in stroke/SE and MB between on-label dose DOACs and off-label RD DOACs.
Steinberg et al., 2018 <sup>26</sup>	USA: 7925 NVAF outpatients on DOAC (mean age 71.0 years, 41.3% female) 3833 RI, 3528 AP, 70 ED, 494 DA Off-label RD (RD use not consistent with FDA SmPC): 9.3% (734) Median follow-up: 1.0 years	Stroke/SE/TIA: 1.35%/year ( <i>n</i> = 91) on-label FD RI or AP, 2.11%/year ( <i>n</i> = 16) off-label RD RI or AP MB: 2.84%/year ( <i>n</i> = 189) on-label FD RI or AP, 4.28%/year ( <i>n</i> = 32) off-label RD RI or AP MI: 0.60%/year ( <i>n</i> = 41) on-label FD RI or AP, 0.78%/year ( <i>n</i> = 6) off-label RD RI or AP Bleeding hospitalization: 2.38%/year ( <i>n</i> = 159) on-label FD RI or AP, 3.60%/year ( <i>n</i> = 27) off-label RD RI or AP All-cause mortality: 2.60%/year ( <i>n</i> = 177) on-label FD RI or AP, 6.77%/year ( <i>n</i> = 52) off-label RD RI or AP	Off-label RD vs. on-label FD in patients receiving either RI or AP showed higher unadjusted rates of stroke/SE/TIA (HR 1.56, 95% CI 0.92–2.67), MB (HR 1.49, 95% CI 1.02–2.18), and overall mortality (HR 2.61, 95% CI 1.86–3.67), with borderline non-significant values after multivariate adjustment.
Amarenco et al., 2019 <sup>29</sup>	Europe, Canada, Israel: subanalysis on 4464 NVAF patients on RI.	MB/stroke/SE/all-cause mortality: 4.8%/year ( <i>n</i> = 157, 4.4%) on-label dose RI, 7.6%/year ( <i>n</i> = 39, 6.7%) off-label RD RI Stroke/SE/MI: 1.9%/year ( <i>n</i> = 62, 1.7%) on-label dose RI, 2.7%/year ( <i>n</i> = 14, 2.4%) off-label RD RI	Off-label RD RI vs. on-label dose RI was associated with a higher risk of the composite of MB/stroke/SE/all-cause

Continued

**Table 1** Continued

Study	Setting, population and definition of off-label RD oFXals' use	Incidence rate/proportion (absolute number) of selected clinical outcomes (unadjusted)	Clinical outcomes associated with off-label RD oFXals use
	Off-label RD RI (RD use not consistent with SmPC) 13.1% (583) Follow-up: 1 years	MB: 2.6%/year ( $n = 86$ , 2.4%) on-label dose RI, 3.9%/year ( $n = 20$ , 3.4%) off-label RD RI ICH: 0.5%/year ( $n = 15$ , 0.4%) on-label dose RI, 1.0%/year ( $n = 5$ , 0.9%) off-label RD RI Fatal bleeding: 0.2%/year ( $n = 7$ , 0.2%) on-label dose RI, 0.4%/year ( $n = 2$ , 0.3%) off-label RD RI All-cause mortality: 1.9%/year ( $n = 62$ , 1.7%) in-label dose RI, 3.1%/year ( $n = 16$ , 2.7%) off-label RD RI	death (HR 1.57, 95% CI 1.10–2.22), but not after multivariate adjustment.
Arbel et al., 2019 <sup>30</sup>	Israel: 8425 NVAF outpatients on on-label FD or off-label RD DOAC (56.4% aged >75 years, 51.9% female) Off-label RD (RD use non consistent with drug label): 39% (3285)	Overall mortality/stroke/MI: 8.7% ( $n = 447$ ) on-label dose DOACs, 22.8% ( $n = 749$ ) off-label RD DOACs Stroke: 1.6% ( $n = 84$ ) on-label dose DOACs, 2.6% ( $n = 86$ ) off-label RD DOACs MI: 0.93% ( $n = 48$ ) on-label dose DOACs, 1.3% ( $n = 44$ ) off-label RD DOACs Bleeding hospitalization: 1.6% ( $n = 80$ ) on-label dose DOACs, 3.1% ( $n = 101$ ) off-label RD DOACs All-cause mortality: 6.9% ( $n = 354$ ) on-label dose DOACs, 20.9% ( $n = 686$ ) off-label RD DOACs	Off-label RD use compared with on-label FD was associated with a higher rate of the composite of overall mortality/stroke/MI (aHR 1.57, 95% CI 1.34–1.83) and a higher rate of bleeding events requiring hospitalization (aHR 1.63, 95% CI, 1.14–2.34).
Cheng et al., 2019 <sup>31</sup>	Taiwan: 2214 NVAF patients on RI <sup>b</sup> (mean age 75.7 years, 36% female) Off-label RD (RD use non consistent with J-ROCKET study <sup>b</sup> ): 26.4% (584) Mean follow-up: 2.10 years	Ischaemic stroke: 0.86%/year ( $n = 32$ ) on-label dose RI, 2.82%/year ( $n = 29$ ) off-label RD RI ICH: 1.14%/year ( $n = 42$ ) on-label dose RI, 1.16%/y ( $n = 12$ ) off-label RD RI	Compared with the on-label dose group, off-label RD RI was associated with an increased risk of ischaemic stroke (aHR 2.75, 95% CI 1.62–4.69), and with a negative net clinical benefit (aHR 1.54, 95% CI 1.02–2.31) in different weighted models, no significant differences in ICH.
Ikeda et al., 2019 <sup>35</sup>	Japan: 6521 NVAF patients on RI <sup>a</sup> and CrCl $\geq 50$ mL/min Off-label RD (RD use not consistent with Japan SmPC <sup>a</sup> ): 35.8% Mean follow-up: 305 days	Stroke/SE/MI: 1.48%/year on-label FD RI, 2.15%/year off-label RD RI Any bleeding: 8.05%/year on-label FD RI, 5.29%/year off-label RD RI MB: 1.63%/year on-label FD RI, 1.34%/year off-label RD RI ICH: 0.64%/year on-label FD RI, 0.75%/year off-label RD RI Fatal bleeding: 0.14%/year on-label FD RI, 0.06%/year off-label RD RI Ischaemic stroke: 1.09%/year on-label FD RI, 1.26%/year off-label RD RI MI: 0.05%/year on-label FD RI, 0.09%/year off-label RD RI	Off-label RD RI resulted in a lower incidence of the primary safety outcome (any bleeding; HR 0.66, 95% CI 0.57–0.76), without a significant difference in MB, and a higher incidence of the primary effectiveness outcome (stroke/SE/MI; HR 1.45, 95% CI 1.10–1.91).
Lee et al., 2019 <sup>38</sup>	Korea: 33 980 NVAF patients with CrCl >50 mL/min, no previous ischaemic stroke/ICH/GIB (mean age 66.9 years, 37.8% female), 20 431 on VKA, 13 549 on RI Off-label RD RI (RD RI use in the absence of a renal indication): 42.8% Median follow-up: 1.4 years	Ischaemic stroke/ICH/hospitalization due to GIB or ICH/all-cause mortality <sup>c</sup> : 7.07%/year ( $n = 349/5196$ ) on-label FD RI, 8.47%/year ( $n = 361/5196$ ) off-label RD RI Ischaemic stroke <sup>c</sup> : 2.16%/year ( $n = 108/5196$ ) on-label FD RI, 2.55%/year ( $n = 110/5196$ ) off-label RD RI MB (ICH/GIB) hospitalization <sup>c</sup> : 2.28%/year ( $n = 114/5196$ ) on-label FD RI, 2.71%/year ( $n = 117/5196$ ) off-label RD RI ICH <sup>c</sup> : 0.89%/year ( $n = 45/5196$ ) on-label FD RI, 0.83%/year ( $n = 36/5196$ ) off-label RD RI	On-label FD RI vs. off-label RD RI showed a significantly lower incidence of the composite of ischaemic stroke/ICH/hospitalization due to GIB or ICH/all-cause death (HR 0.85, 95% CI 0.74–0.99), but no significant difference for any of the single outcomes. <sup>c</sup>

Continued

**Table 1** Continued

Study	Setting, population and definition of off-label RD oFXals' use	Incidence rate/proportion (absolute number) of selected clinical outcomes (unadjusted)	Clinical outcomes associated with off-label RD oFXals use
Murata <i>et al.</i> , 2019 <sup>40</sup>	Japan: 1676 NVAF outpatients on DOAC (mean age 71.7 years, 28.5% females), RI <sup>a</sup> 45.5%, AP 25.6%, ED 1.9%, DA 27.1% Off-label RD (RD use not consistent with Japan SmPC <sup>b</sup> ): 22.2% Median follow-up: 39.3 months	GIB hospitalization <sup>c</sup> : 1.41%/year ( <i>n</i> = 71/5196) on-label FD RI, 1.89%/year ( <i>n</i> = 82/5196) off-label RD RI All-cause mortality <sup>c</sup> : 3.60%/year ( <i>n</i> = 182/5196) on-label FD RI, 4.32%/year ( <i>n</i> = 189/5196) off-label RD RI Ischaemic stroke/TIA/SE: 1.17%/year ( <i>n</i> = 25, 3.3%) on-label FD DOACs, 2.07%/year ( <i>n</i> = 27, 5.6%) on-label RD DOACs, 1.02%/year ( <i>n</i> = 11, 2.9%) off-label RD DOACs MB: 1.21%/year ( <i>n</i> = 26, 3.5%) on-label FD DOACs, 1.45%/year ( <i>n</i> = 19, 4.0%) on-label RD DOACs, 0.64%/year ( <i>n</i> = 7, 1.9%) off-label RD DOACs ICH: 0.46%/year ( <i>n</i> = 10, 1.3%) on-label FD DOACs, 0.53%/year ( <i>n</i> = 7, 1.5%) on-label RD DOACs, 0.37%/year ( <i>n</i> = 4, 1.1%) off-label RD DOACs All-cause mortality: 0.64%/year ( <i>n</i> = 14, 1.9%) on-label FD DOACs, 4.07%/year ( <i>n</i> = 54, 11.3%) on-label RD DOACs, 1.28%/year ( <i>n</i> = 14, 3.8%) off-label RD DOACs	Ischaemic stroke/TIA/SE, mortality, and MB did not significantly differ between the on-label FD, and off-label RD groups, before and after propensity score matching.
Navarro-Almenzar <i>et al.</i> , 2019 <sup>49</sup>	Spain: 2494 NVAF patients on DOAC (mean age 76 years, 52.9% female), RI 41.1%, AP 38.5%, ED 2.8%, DA 17.6% Off-label DOAC dose in 517 patients (23.5%), FXal mainly underdosed (dose not consistent with SmPC); RI 26.1%, AP 21.2%, ED 23.9%, DA 22.8% Mean follow-up: 20.2 months	Ischaemic stroke: 1.8%/year ( <i>n</i> = 52/1682, 3.1%) on-label dose DOACs, 2.0%/year ( <i>n</i> = 15/441, 3.4%) off-label RD DOACs MB: 3.0%/year ( <i>n</i> = 87/1682, 5.2%) on-label dose DOACs, 3.3%/year ( <i>n</i> = 25/441, 5.7%) off-label RD DOACs ICH: 0.3%/year ( <i>n</i> = 10/1682, 0.6%) on-label dose DOACs, 0.4%/year ( <i>n</i> = 3/441, 0.7%) off-label RD DOACs All-cause mortality: 5.1%/year ( <i>n</i> = 142/1682, 8.4%) on-label dose DOACs, 9.3%/year ( <i>n</i> = 69/441, 15.6%) off-label RD DOACs	Off-label RD patients showed a non-significant higher overall mortality, and no differences in stroke/TIA and MB.
Briasoulis <i>et al.</i> , 2020 <sup>44</sup>	USA: 27 747 Medicare beneficiaries with AF, 19 712 on RI, 8035 on DA Off-label RD RI (RD use without eGFR <50 mL/min or drug–drug interactions): 12.9% (2551) Mean follow-up: 13 months	Ischaemic stroke: 0.026/year ( <i>n</i> = 256) on-label FD RI, 0.057/year ( <i>n</i> = 176) on-label RD RI, 0.040/year ( <i>n</i> = 89) off-label RD RI MB: 0.043/year ( <i>n</i> = 426) on-label FD RI, 0.099/year ( <i>n</i> = 307) on-label RD RI, 0.067/year ( <i>n</i> = 147) off-label RD RI ICH: 0.004/year ( <i>n</i> = 38) on-label FD RI, 0.008/year ( <i>n</i> = 25) on-label RD RI, 0.006/year ( <i>n</i> = 13) off-label RD RI GIB: 0.034/year ( <i>n</i> = 341) on-label FD RI, 0.078/year ( <i>n</i> = 243) on-label RD RI, 0.050/year ( <i>n</i> = 111) off-label RD RI	Compared with the on-label FD RI group, the off-label RD RI group showed similar rates of stroke, ICH and GIB, and a higher rate of MB (HR 1.35, 95% CI 1.12–1.6), that was not confirmed after controlling for several patients' characteristics in propensity-matched samples.
Cho <i>et al.</i> , 2020 <sup>20</sup>	Korea: 16 568 NVAF outpatients on OAT and no indication to RD use (56.1% female) Off-label RD (RD use inconsistent with SmPC): 51.6% (8549/16 568 patients on DOAC); RI 50.6% (mean age 71.4 years), AP 53.0% (mean age 73.0 years) Median follow-up: 15 months	Ischaemic stroke/SE: 2.30%/year ( <i>n</i> = 197, 2.5%) on-label FD DOACs, 2.38%/year ( <i>n</i> = 226, 2.6%) off-label RD DOACs; 2.47%/year ( <i>n</i> = 128, 2.7%) on-label FD RI, 2.02%/year ( <i>n</i> = 106, 2.2%) off-label RD RI; 2.04%/year ( <i>n</i> = 69, 2.1%) on-label FD AP, 2.88%/year ( <i>n</i> = 120, 3.3%) off-label RD AP MB: 1.51%/year ( <i>n</i> = 151, 1.9%) on-label FD DOACs, 1.99%/year ( <i>n</i> = 187, 2.2%) off-label RD DOACs; 1.69%/year ( <i>n</i> = 99, 2.1%) on-label FD RI, 2.20%/year ( <i>n</i> = 119, 2.4%) off-label RD RI; 1.24%/year ( <i>n</i> = 52, 1.6%) on-label FD AP, 1.72%/year ( <i>n</i> = 68, 1.9%) off-label RD AP All-cause mortality: 1.59%/year ( <i>n</i> = 135, 1.7%) on-label FD DOACs, 2.38%/year ( <i>n</i> = 205, 2.4%) off-label RD DOACs; 1.70%/year ( <i>n</i> = 86, 1.8%) on-label FD RI, 1.89%/year	Off-label RD RI vs. on-label FD RI: no significant differences in ischaemic stroke/SE, overall mortality and MB. Off-label RD AP vs. in-label FD AP: non-significant increase on ischaemic stroke/SE (aHR 1.27, 95% CI 1.00–1.63), higher overall mortality (aHR 1.49, 95% CI 1.12–1.97), no significant differences in MB.

Continued

**Table 1** Continued


Study	Setting, population and definition of off-label RD oFXals' use	Incidence rate/proportion (absolute number) of selected clinical outcomes (unadjusted)	Clinical outcomes associated with off-label RD oFXals use
Eschler et al., 2020 <sup>50</sup>	Switzerland: 19 662 consecutive emergency department admissions, 1721 (9%) on OAT (mean age 77 years, 47% female, 63.2% for NVAF): VKAs 40.7%, RI 35.8%, AP 18.7%, ED 4.4%, DA 0.5% 175 (17.1%) of DOACs off-label RD (RD use not consistent with SmPC, according to diagnosis); 345 (20%) of the overall sample was underdosed (including subtherapeutic VKAs) 166 cases (9.6%) presented to the emergency department with bleeding	(n = 95, 2.0%) off-label RD RI; 1.42%/year (n = 49, 1.5%) on-label FD AP, 3.04%/year (n = 110, 3.0%) off-label RD AP Bleeding presentation in the emergency department: 9.6% of patients on OAT (n = 166)	Only use of ASA (OR 1.7, 95% CI 1.0–2.8) was associated with bleeding presentation in the emergency department and a higher likelihood of severe bleeding (P=0.042). No significant association among anticoagulant molecules and bleeding or in-hospital mortality.
Inoue et al., 2020 <sup>45</sup>	Japan: 6306 NVAF patients on AP (72.8% aged ≥70 years, 41.1% female), Off-label RD (RD use not consistent with Japan SmPC): 15% Mean follow-up: 17.4 months	Ischaemic stroke/SE/TIA: 0.70%/year (n = 33) on-label FD AP, 1.69%/year (n = 37) on-label RD AP, 0.95%/year (n = 13) off-label RD AP MB: 2.00%/year (n = 94) on-label FD AP, 3.30%/year (n = 72) on-label RD AP, 2.50%/year (n = 34) off-label RD AP ICH: 0.57%/year (n = 27) on-label FD AP, 1.14%/year (n = 25) on-label RD AP, 0.88%/year (n = 12) off-label RD AP Major GIB: 0.89%/year (n = 42) on-label FD AP, 1.60%/year (n = 35) on-label RD AP, 0.80%/year (n = 11) off-label RD AP Any bleeding: 4.80%/year (n = 221) on-label FD AP, 7.01%/year (n = 150) on-label RD AP, 5.53%/year (n = 74) off-label RD AP	AP dosing not associated with MB or ischaemic stroke/SE/TIA.
Lee et al., 2020 <sup>47</sup>	Korea: 3733 NVAF outpatients on DOAC (mean age 68.0 years, 37.6% female), 2659 on warfarin Off-label RD DOAC (RD use not consistent with Korea SmPC) 20.3% Mean follow-up: 6.3 months (DOAC group) vs. 9.9 months (warfarin group)	Ischaemic stroke/SE/MI/intracavitary thrombus: 1.35%/year warfarin, 1.05%/year on-label FD DOACs, 1.94%/year on-label RD DOACs, 2.73%/year off-label RD DOACs MB: 2.14%/year warfarin, 0.89%/year on-label FD DOACs, 1.23%/year on-label RD DOACs, 1.46%/year off-label RD DOACs	Compared with warfarin, off-label RD group had an increased risk of ischaemic stroke/SE/MI/intracavitary thrombus (aHR 2.51, 95% CI 1.28–4.93) in several adjusted models, and a higher risk of MB in the unadjusted model (HR 6.16; 95% CI 1.60–23.62), but not in the adjusted model.

AF, atrial fibrillation; aHR, adjusted hazard ratio; AP, apixaban; ASA, acetylsalicylic acid; CI, confidence interval; CRNMB, clinically relevant non-major bleeding; CV, cardiovascular; DA, dabigatran; DOAC, direct oral anticoagulant; ED, edoxaban; eGFR, estimated glomerular filtration rate; FD, full dose; FDA, Food and Drug Administration; FXaI, factor Xa inhibitor; GIB, gastro-intestinal bleeding; HR, hazard ratio; ICH, intracranial haemorrhage; MB, major bleeding; MI, myocardial infarction; NVAF, non-valvular atrial fibrillation; OAT, oral anticoagulant therapy; OR, odds ratio; RD, reduced dose; RI, rivaroxaban; SE, systemic embolism; SmPC, summary of product characteristics; TIA, transient ischaemic attack; VKA, vitamin K antagonist.

<sup>a</sup>In Japan, approved doses of RI are 15 mg once daily FD and 10 mg once daily RD, with the same criteria for RD use as European-approved doses.

<sup>b</sup>Including patients both in Japan-approved (i.e. 15 mg/10 mg once daily) and in European-approved doses (i.e. 20 mg/15 mg once daily), considering only 10 mg once daily as underdosed in absence of criteria for RD use.

<sup>c</sup>In propensity score-matched cohorts.



always defined as the prescription of RD oFXals not in keeping with the SmPC-specified dose reduction criteria.

Table 1 summarizes the main efficacy and safety outcome results coming from real-world studies which evaluated the clinical implications of off-label RD use. In the ORBIT-AF II study, underdosing was associated with increased cardiovascular hospitalization, without reduced bleeding events and/or bleeding-related hospitalizations.<sup>13</sup> In the STANDARD study, including 6306 NVAF subjects on apixaban, there was no evidence of increasing safety (MB or any bleeding event) with the use of off-label RD.<sup>45</sup> In a recent retrospective analysis including 1023 patients on DOACs presenting in an emergency department, no significant difference was found with respect to bleeding according to DOAC dosing.<sup>50</sup> In a large sample of 16 568 Korean outpatients, compared with warfarin, off-label RD rivaroxaban was associated with a lower risk of thromboembolic events and all-cause mortality, with a similar risk of MB, whereas off-label RD apixaban was associated with similar risks of thromboembolic events, all-cause mortality and MB.<sup>20</sup> Among 8425 NVAF patients, DOAC underdosing was associated with significantly reduced effectiveness without a significant safety benefit.<sup>30</sup> In a retrospective analysis including 6392 NVAF Asian outpatients, DOAC underdosing was associated with a 2.5-fold increased risk of thromboembolism compared with warfarin, with a comparable risk of MB.<sup>47</sup>

Potential underdosing in 14 865 NVAF patients who initiated DOAC therapy and did not meet renal criteria for RD use was found to be associated with a higher risk of stroke, particularly in apixaban-treated patients, without a significant difference in MB events; however, lack of data on BW strongly limited the correct assessment of off-label RD use in apixaban-treated patients.<sup>22</sup> Briasoulis et al.<sup>44</sup>

reported that patients who received off-label RD rivaroxaban (12.9%) had an increased risk of MB, which was not significant after propensity score matching. On the contrary, clinical outcomes were not worse for underdosed rather than correctly -dosed subjects enrolled in the prospective multicentre SAKURA AF registry in Japan.<sup>40</sup> In a retrospective Spanish study of 2494 NVAF patients on DOAC, underdosing was associated with a non-significant higher death rate, without differences in MB and stroke.<sup>49</sup> After adjusting for patients' characteristics by propensity scoring and inverse probability of treatment weighting, compared with patients who received the recommended dose, patients enrolled in the XAPASS study who received off-label RD rivaroxaban experienced comparable rates of MB and higher rates of stroke/SE and myocardial infarction.<sup>35</sup> Very similar findings were reported by Cheng et al.<sup>31</sup> in 2214 rivaroxaban-treated patients in Taiwan; compared with on-label dosing, off-label RD rivaroxaban was associated with an increased risk of ischaemic stroke, and a negative net clinical benefit in different weighted models. In a Korean study, on-label FD rivaroxaban showed better results for the composite clinical outcome (ischaemic stroke, intracranial haemorrhage, hospitalization for GIB, and all-cause death) compared with off-label RD.<sup>38</sup> Using data from the XANTUS study, Amarenco et al.<sup>29</sup> reported that use of off-label RD rivaroxaban was associated with a trend to less favourable outcomes (MB, stroke/SE, and death), association not confirmed when correcting for patients' characteristics at multivariate analysis. In a small retrospective study including 354 NVAF patients aged 80 years and over with non-severe frailty, 42 of 273 patients on DOAC (15.4%) were underdosed, without differences in the incidence of bleeding and thromboembolic events.<sup>86</sup> Paciaroni et al.<sup>87</sup> retrospectively investigated the risk factors for



cerebrovascular ischaemic events occurring during DOAC therapy for stroke prevention in atrial fibrillation in a sample of 713 cases (641 ischaemic strokes and 72 TIAs) and 700 controls: on multivariate analysis, use of off-label RD was associated with a three-fold increased risk of ischaemic events. In a prospective cohort study on 1124 atrial fibrillation patients aged 85 years and older treated with vitamin K antagonists (58.7%) or DOACs (41.3%), no thrombotic events occurred in the small group of underdosed DOAC patients.<sup>88</sup> Recent studies demonstrated that oFXals' underdosing was associated with a higher stroke severity in patients admitted with ischaemic stroke,<sup>89</sup> and with a higher rate of major vascular occlusion in patients admitted with suspected ischaemic stroke.<sup>90</sup>

In conclusion, despite inherent limitations of observational studies, and with few exceptions,<sup>40,86,88</sup> there is consistent evidence that underdosing of oFXals is not associated with a significant reduction of bleeding events and is possibly associated with an increased risk of thromboembolic events.

## Conclusions

Despite the well-demonstrated greater net clinical benefit of DOACs compared with warfarin in the general population and in older patients,<sup>91,92</sup> there is still a persistent underuse of OAT<sup>53,93</sup> and an increasing use of off-label RD of oFXals.<sup>14</sup> Our literature review, summarized in *Figure 1*, demonstrated that a substantial proportion of oFXals' underdosing may be voluntary, suggesting a cautious approach to patients perceived to be at high risk of bleeding. However, available evidence suggests that patients' characteristics (e.g. advanced age, comorbidity, anaemia, previous bleedings, concomitant therapy with antiplatelet drugs or NSAIDs) and underlying GI pathology, rather than OAT intensity, are associated with the risk of bleeding events. Indeed, in oFXals' RCTs, the rates of MB were consistently higher among patients treated with RD rather than in those treated with FD. Moreover, correct use of RD had reassuringly the same efficacy and safety as FD oFXals compared with warfarin.<sup>66</sup> Real-life studies do not provide evidence of a sizeable net clinical benefit by using off-label RD oFXals, but rather suggest an increased risk of adverse events, including hospitalizations for cardiovascular causes and stroke, without a significant reduction of bleeding events.

All three oFXals show a first-order kinetic, which means that, at the dosage range tested, they show a linear correlation between their drug plasma concentrations (DPCs) and the pharmacodynamic (PD) inhibition of clotting factor X activated (FXa), without any tendency to reach a plateau. Such linearity is consistent and independent of age and sex.<sup>94</sup> On these bases, an inverse and a direct relationship of DPC with the probability of stroke/SE and MB, respectively, have been observed, although within-patient clinical variability complicates the interpretation of these results.<sup>95</sup>

Indeed, it has been reported that treatment with off-label RD DOACs compared with on-label dose was associated with lower DPCs,<sup>96</sup> and that C-trough levels in the lowest level class were associated with a significantly increased incidence of thromboembolic events.<sup>97</sup> Use of an RD implicates halving the dose of apixaban (from 5 mg to 2.5 mg) and edoxaban (from 60 mg to 30 mg), while reducing of only 25% the dose of rivaroxaban (from 20 mg to 15 mg) and of

33% (from 15 mg to 10 mg) in Japanese patients. Halving the dose of apixaban or edoxaban is associated to an approximate 50% proportional reduction of their maximum DPCs.<sup>76,98</sup> However, it must be taken into consideration that in the ENGAGE AF-TIMI 48 trial, the predefined halving of edoxaban dose was associated to only an approximate 25% reduction of DPC and anti-FXa activity.<sup>76</sup> Moreover, the investigation of the effects of low BW ( $\leq 50$  kg) on pharmacokinetics and PD showed approximately 27% higher apixaban peak concentration (C<sub>max</sub>) and area under the curve,<sup>99</sup> and a 24% higher rivaroxaban C<sub>max</sub> resulting in a 15% increase in prolongation of prothrombin time.<sup>100</sup> Thus, by considering the criteria for edoxaban dose reduction, such as BW  $\leq 60$  kg, estimated CrCl 30–50 mL/min, or concomitant use of verapamil or quinidine, DPCs of the 30 mg dose were similar to those reached with 60 mg.<sup>76</sup> Very similar results were obtained for apixaban where a 25% reduction of DPC was observed in patients treated with 2.5 mg vs. 5 mg when two out of three dose reduction criteria of the ARISTOTLE study were met.<sup>101</sup> Finally, the DPCs of on-label rivaroxaban FD and RD were also superimposable.<sup>102</sup> These results suggest that DPCs, and thus activities, of all oFXals in patients prescribed on-label RDs are similar to those observed with on-label FD, thereby reinforcing prescription according to recommended dose.

In our view, the main strength of the present study is the physician-centred approach we used to assess the reasons underlying the decision to underdose oFXals in selected patients, the inconsistent and frail pharmacologic and clinical background supporting this strategy, and the clinical safety and efficacy implications of underdosing in real-life studies. The major limitation of the present study is that the evidence about the clinical implications of underdosing derives from observational studies, which have inherent weaknesses. Most of these studies are registry-based, mainly retrospective, with potential for residual confounding from unmeasured variables, such as over-the-counter use of aspirin, polypharmacy, drug-drug interactions, body size and general health status. Moreover, these studies are heterogeneous, differing for clinical setting, country and ethnic groups, definition of potential underdosing and clinical outcomes considered. Eventually, most patients were treated with apixaban and rivaroxaban, with a small proportion of patients on edoxaban. Notwithstanding these limitations, the available evidence is quite consistent and does not suggest a potential benefit from oFXals' underdosing. At the same time, even if current evidence is not sufficient to allow any speculation about possible safety or efficacy differences among different oFXals used at inappropriate RDs, there are quite consistent data that underdosing is more frequent, and has the potential to be particularly detrimental, in apixaban-treated patients. Being hard to imagine the ethical and practical feasibility of an RCT assessing the potential clinical benefit of off-label oFXal RDs in selected patients, only prospective, dedicated, observational real-life studies involving subjects at high risk of underdosing (older polypathologic NVAf patients) might further shed some light on this topic. In these patients, OAT prescription is often a troublesome decision, involving a global evaluation of health, residual life-expectancy, functional and cognitive status, rather than a simple addition of variables within cardio-embolic and bleeding risk scales.<sup>53,54</sup> In keeping with current recommendations not to undertreat older frail patients,<sup>55</sup> our review demonstrates that oFXals' underdosing may be associated with a reduced efficacy without greater safety, thereby implying

a poor benefit and possible harm from this strategy. At the moment, less is not more, in this case.

## Supplementary material

Supplementary material is available at *European Heart Journal – Cardiovascular Pharmacotherapy* online.

**Conflict of interest:** M.B. reports receiving consulting fees from Bayer, Boehringer, BMS-Pfizer and Daiichi-Sankyo. A.C. reports receiving consulting fees from Bristol-Myers, Daiichi-Sankyo, Mylan, AstraZeneca, Sanofi, Recordati, Novartis, MSD, Mediolanum DOC, Pfizer. N.F. reports receiving consulting fees Bristol-Myers, Daiichi-Sankyo, Mylan. E.B., G.I., M.G., D.P., N.M., and G.M.D.F. have nothing to disclose.

## References

- Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener H-C, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009;**361**:1139–1151.
- Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KAA, Califf RM; the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med* 2011;**365**:883–891.
- Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FWA, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2011;**365**:981–992.
- Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz J, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2013;**369**:2093–2104.
- Ieko M, Naitoh S, Yoshida M, Takahashi N. Profiles of direct oral anticoagulants and clinical usage-dosage and dose regimen differences. *J Intensive Care* 2016;**4**:19.
- Harder S, Graff J. Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. *Eur J Clin Pharmacol* 2013;**69**:1617–1633.
- Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haessler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H, Lip GYH, Weitz J, Fauchier L, Lane D, Boriani G, Goette A, Keegan R, MacFadyen R, Chiang C-E, Joung B, Shimizu W; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. *Eur Heart J* 2018;**39**:1330–1393.
- Healey JS, Eikelboom J, Wallentin L, Ezekowitz MD, Connolly SJ, Reilly P, Joyner CD, Lewis BS, Themeles E, Yusuf S. Effect of age and renal function on the risks of stroke and major bleeding with dabigatran compared to warfarin: an analysis from the RE-LY study. *J Am Coll Cardiol* 2010;**55**:A4.E37.
- Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener H-C, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. *Circulation* 2011;**123**:2363–2372.
- Lip GYH, Clemens A, Noack H, Ferreira J, Connolly SJ, Yusuf S. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. *Thromb Haemost* 2014;**111**:933–942.
- Staerk L, Gerds TA, Lip GYH, Ozanne B, Bonde AN, Lamberts M, Fosbøl EL, Torp-Pedersen C, Gislason GH, Olesen JB. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study. *J Intern Med* 2018;**283**:45–55.
- Ruiz Ortiz M, Muñoz J, Raña Míguez P, Roldán I, Marín F, Asunción Esteve-Pastor M, Cequier A, Martínez-Sellés M, Bertomeu V, Anguita M; FANTASIA study Investigators. Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIA Registry. *Europace* 2018;**20**:1577–1583.
- Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel J, Singer DE, Peterson ED, Piccini JP; ORBIT-AF Investigators and Patients. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II Registry. *J Am Coll Cardiol* 2016;**68**:2597–2604.
- Santos J, António N, Rocha M, Fortuna A. Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: a systematic review. *Br J Clin Pharmacol* 2020;**86**:533–547.
- Gibson CM, Smith CB, Davis S, Scalese MJ. Assessment of apixaban prescribing patterns for nonvalvular atrial fibrillation in hospitalized patients. *Ann Pharmacother* 2018;**52**:54–59.
- Angel Y, Zeltser D, Berliner S, Ingbir M, Shapira I, Shenhar-Tsarfaty S, Rogowski O. Hospitalization as an opportunity to correct errors in anticoagulant treatment in patients with atrial fibrillation. *Br J Clin Pharmacol* 2019;**85**:2838–2847.
- McAlister FA, Garrison S, Kosowan L, Ezekowitz JA, Singer A. Use of direct oral anticoagulants in Canadian Primary Care Practice 2010-2015: a cohort study from the Canadian Primary Care Sentinel Surveillance Network. *J Am Heart Assoc* 2018;**7**:e007603.
- Sanghai S, Wong C, Wang Z, Clive P, Tran W, Waring M, Goldberg R, Hayward R, Szczyński JS, McManus DD. Rates of potentially inappropriate dosing of direct-acting oral anticoagulants and associations with geriatric conditions among older patients with atrial fibrillation: the SAGE-AF study. *J Am Heart Assoc* 2020;**9**:e014108.
- Franchi C, Antoniazzi S, Proietti M, Nobili A, Mannucci PM, SIM-AF Collaborators. Appropriateness of oral anticoagulant therapy prescription and its associated factors in hospitalized older people with atrial fibrillation. *Br J Clin Pharmacol* 2018;**84**:2010–2019.
- Cho MS, Yun JE, Park JJ, Kim YJ, Lee J, Kim H, Park D-W, Nam G-B. Pattern and impact of off-label underdosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation who are indicated for standard dosing. *Am J Cardiol* 2020;**125**:1332–1338.
- Tellor KB, Wang M, Green MS, Armbruster AL. Evaluation of apixaban for the treatment of nonvalvular atrial fibrillation with regard to dosing and safety in a community hospital. *J Pharm Technol* 2017;**33**:140–145.
- Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. *J Am Coll Cardiol* 2017;**69**:2779–2790.
- Buchholz A, Ueberham L, Gorczynska K, Dinov B, Hilbert S, Dagnes N, Husser D, Hindricks G, Bollmann A. Initial apixaban dosing in patients with atrial fibrillation. *Clin Cardiol* 2018;**41**:671–676.
- Moudallel S, Steurbaut S, Cornu P, Dupont A. Appropriateness of DOAC prescribing before and during hospital admission and analysis of determinants for inappropriate prescribing. *Front Pharmacol* 2018;**9**:1220.
- Sato T, Aizawa Y, Fuse K, Fujita S, Ikeda Y, Kitazawa H, Takahashi M, Okabe M. The comparison of inappropriate-low-doses use among 4 direct oral anticoagulants in patients with atrial fibrillation: from the database of a single-center registry. *J Stroke Cerebrovasc Dis* 2018;**27**:3280–3288.
- Steinberg BA, Shrader P, Pieper K, Thomas L, Allen LA, Ansell J, Chan PS, Ezekowitz MD, Fonarow GC, Freeman JV, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli GV, Reiffel JA, Singer DE, Peterson ED, Piccini JP; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) II Investigators. Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants: results from ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). *J Am Heart Assoc* 2018;**7**:e007633.
- Umei M, Kishi M, Sato T, Shindo A, Toyoda M, Yokoyama M, Matsushita M, Ohnishi S, Yamasaki M. Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients. *J Arrhythm* 2017;**33**:475–482.
- Ablefoni K, Buchholz A, Ueberham L, Hilbert S, Dagnes N, Husser D, Hindricks G, Bollmann A. Initial rivaroxaban dosing in patients with atrial fibrillation. *Clin Cardiol* 2019;**42**:873–880.
- Amarenco P, Haas S, Hess S, Kirchhoff P, Lambelet M, Bach M, Turpie AGG, Camm AJ. Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study. *Eur Heart J Cardiovasc Pharmacother* 2019;**5**:70–79.
- Arbel R, Sergienko R, Hammerman A, Greenberg-Dotan S, Batat E, Avnery O, Ellis MH. Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation. *Am J Med* 2019;**132**:847–855.e3.

31. Cheng W-H, Chao T-F, Lin Y-J, Chang S-L, Lo L-W, Hu Y-F, Tuan T-C, Liao J-N, Chung F-P, Lip GYH, Chen S-A. Low-dose rivaroxaban and risks of adverse events in patients with atrial fibrillation. *Stroke* 2019;**50**:2574–2577.
32. Falissard B, Picard F, Mahe I, Hanon O, Touzé E, Danchin N, Lamy F-X, Ricci L, Steg PG. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: the PAROS cross-sectional study of routine clinical practice. *Arch Cardiovasc Dis* 2019;**112**:400–409.
33. García Rodríguez LA, Martín-Pérez M, Vora P, Roberts L, Balabanova Y, Brobert G, Fatoba S, Suzart-Woischnik K, Schaefer B, Ruigomez A. Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK. *BMJ Open* 2019;**9**:e031341.
34. Gustafson WL, Saunders J, Vazquez SR, Jones AE, Witt DM. Real-world study of direct oral anticoagulant dosing patterns in patients with atrial fibrillation. *Pharm Pract (Granada)* 2019;**17**:1709.
35. Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Minematsu K, Miyamoto S, Murakawa Y, Iwashiro S, Kidani Y, Okayama Y, Sunaya T, Sato S, Yamanaka S. Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings. *J Thromb Thrombolysis* 2019;**48**:653–660.
36. Jang BM, Lee OS, Shin EJ, Cho EJ, Suh SY, Cho YS, Lee MK, Rhie SJ. Factors related to inappropriate edoxaban use. *J Clin Pharm Ther* 2019;**44**:760–767.
37. Kartas A, Samaras A, Vasdeki D, Dividis G, Fotos G, Paschou E, Forozidou E, Tsoukra P, Kotsi E, Goulas I, Efthimiadis G, Karvounis H, Tzikas A, Giannakoulas G. Flaws in anticoagulation strategies in patients with atrial fibrillation at hospital discharge. *J Cardiovasc Pharmacol Ther* 2019;**24**:225–232.
38. Lee S-R, Choi E-K, Han K-D, Jung J-H, Oh S, Lip GYH. Optimal rivaroxaban dose in asian patients with atrial fibrillation and normal or mildly impaired renal function. *Stroke* 2019;**50**:1140–1148.
39. Lee S-R, Lee YS, Park J-S, Cha M-J, Kim T-H, Park J, Park J-K, Lee J-M, Kang K-W, Shim J, Uhm J-S, Kim J, Kim C, Kim J-B, Park HW, Joung B, Choi E-K. Label adherence for non-vitamin K antagonist oral anticoagulants in a prospective cohort of Asian patients with atrial fibrillation. *Yonsei Med J* 2019;**60**:277–284.
40. Murata N, Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, Oiwa K, Matsumoto M, Kojima T, Hanada S, Nomoto K, Arima K, Takahashi F, Kotani T, Ikeya Y, Fukushima S, Itoh S, Kondo K, Chiku M, Ohno Y, Onikura M, Hirayama A; SAKURA AF Registry Investigators. Clinical outcomes of off-label dosing of direct oral anticoagulant therapy among Japanese patients with atrial fibrillation identified from the SAKURA AF Registry. *Circ J* 2019;**83**:727–735.
41. Ono T, Ikemura N, Kimura T, Ueda I, Tanaka H, Tokuda H, Yajima N, Matsumura K, Suzuki M, Fukuda K, Kohsaka S, Takatsuki S. Contemporary trend of reduced-dose non-vitamin K anticoagulants in Japanese patients with atrial fibrillation: a cross-sectional analysis of a multicenter outpatient registry. *J Cardiol* 2019;**73**:14–21.
42. Sheikh-Taha M, Deeb ME. Assessment of non-vitamin K oral anticoagulants use in a tertiary care center in the USA: a chart review of 909 patients. *Am J Cardiovasc Drugs* 2019;**19**:195–201.
43. Badreldin HA, Alreshoud L, Altoukhi R, Vasudevan S, Samil W, Mohamed MSA. Prevalence and predictors of inappropriate apixaban dosing in patients with non-valvular atrial fibrillation at a large tertiary academic medical institution. *Drugs Ther Perspect* 2020;**36**:83–88.
44. Briasoulis A, Gao Y, Inampudi C, Alvarez P, Asleh R, Chrischilles E, Leira EC, Vaughan-Sarrazin M. Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses. *BMC Cardiovasc Disord* 2020;**20**:42.
45. Inoue H, Umeyama M, Yamada T, Hashimoto H, Komoto A, Yasaka M. Safety and effectiveness of reduced-dose apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: a sub-analysis of the STANDARD study. *J Cardiol* 2020;**75**:208–215.
46. Yagi N, Suzuki S, Arita T, Otsuka T, Semba H, Kano H, Matsuno S, Kato Y, Uejima T, Oikawa Y, Yajima J, Matsuhama M, Yamashita T. Creatinine clearance and inappropriate dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation. *Heart Vessels* 2020;**35**:110–117.
47. Lee K-N, Choi J-I, Boo KY, Kim DY, Kim YG, Oh S-K, Baek Y-S, Lee DI, Roh S-Y, Shim J, Kim JS, Kim Y-H. Effectiveness and safety of off-label dosing of non-vitamin K antagonist anticoagulant for atrial fibrillation in Asian patients. *Sci Rep* 2020;**10**:1801.
48. Miyazaki M, Matsuo K, Uchiyama M, Nakamura Y, Sakamoto Y, Misaki M, Tokura K, Jimi S, Okamura K, Adachi S, Yamamoto T, Shirai K, Urata H, Imakyure O. Inappropriate direct oral anticoagulant dosing in atrial fibrillation patients is associated with prescriptions for outpatients rather than inpatients: a single-center retrospective cohort study. *J Pharm Health Care Sci* 2020;**6**:2.
49. Navarro-Almenzar B, Cerezo-Manchado JJ, Caro-Martinez C, García-Candel F, Flores Blanco PJ, Ruiz GE, Andreu Cayuelas JM, Montoya FA, Cascales A, Lova Navarro A, García Alberola A, Andrés Pascual Figal D, Bailen Lorenzo JL, Manzano-Fernández S. Real-life behaviour of direct oral anticoagulants in a Spanish cohort with non-valvular atrial fibrillation: refase Registry. *Curr Med Res Opin* 2019;**35**:2035–2041.
50. Eschler CM, Woitok BK, Funk G-C, Walter P, Maier V, Exadaktylos AK, Lindner G. Oral anticoagulation in patients in the emergency department: high rates of off-label doses, no difference in bleeding rates. *Am J Med* 2020;**133**:599–604.
51. Kooistra HAM, Calf AH, Piersma-Wichers M, Kluin-Nelemans HC, Izaks GJ, Veeger NJGM, Meijer K. Risk of bleeding and thrombosis in patients 70 years or older using vitamin K antagonists. *JAMA Intern Med* 2016;**176**:1176–1183.
52. Killu AM, Granger CB, Gersh BJ. Risk stratification for stroke in atrial fibrillation: a critique. *Eur Heart J* 2019;**40**:1294–1302.
53. Bo M, Grisoglio E, Brunetti E, Falcone Y, Marchionni N. Oral anticoagulant therapy for older patients with atrial fibrillation: a review of current evidence. *Eur J Intern Med* 2017;**41**:18–27.
54. Bo M, Marchionni N. Practical use of direct oral anticoagulants (DOACs) in the older patients with atrial fibrillation. *Eur J Intern Med* 2020;**71**:32–38.
55. Steffel J, Heidbuchel H. 'Ten Commandments' of the EHRA Guide for the Use of NOACs in AF. *Eur Heart J* 2018;**39**:1322–1322.
56. Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. *J Am Coll Cardiol* 2014;**64**:1128–1139.
57. Sakaguchi T, Osanai H, Murase Y, Ishii H, Nakashima Y, Asano H, Suzuki S, Takefuji M, Inden Y, Sakai K, Murohara T, Ajioka M. Monitoring of anti-Xa activity and factors related to bleeding events: a study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban. *J Cardiol* 2017;**70**:244–249.
58. Testa S, Legnani C, Antonucci E, Paoletti O, Dellanocce C, Cosmi B, Pengo V, Poli D, Morandini R, Testa R, Tripodi A, Palareti G; Coordinator of START2-Register. Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants. *J Thromb Haemost* 2019;**17**:1064–1072.
59. Suwa M, Morii I, Kino M. Rivaroxaban or apixaban for non-valvular atrial fibrillation—efficacy and safety of off-label under-dosing according to plasma concentration. *Circ J* 2019;**83**:991–999.
60. Coleman CI, Antz M, Bowrin K, Evers T, Simard EP, Bonnemeier H, Cappato R. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. *Curr Med Res Opin* 2016;**32**:2047–2053.
61. Essien UR, Holmes DN, Jackson LR, Fonarow GC, Mahaffey KW, Reiffel JA, Steinberg BA, Allen LA, Chan PS, Freeman JV, Blanco RG, Pieper KS, Piccini JP, Peterson ED, Singer DE. Association of race/ethnicity with oral anticoagulant use in patients with atrial fibrillation. *JAMA Cardiol* 2018;**3**:1174–1182.
62. Lee JM, Kim T-H, Cha M-J, Park J, Park J-K, Kang K-W, Shim J, Uhm J-S, Kim J, Park HW, Lee YS, Choi E-K, Kim C-S, Joung B, Kim J-B. Gender-related differences in management of nonvalvular atrial fibrillation in an Asian population. *Korean Circ J* 2018;**48**:519–528.
63. Sherwood MW, Nessel CC, Hellkamp AS, Mahaffey KW, Piccini JP, Suh E-Y, Becker RC, Singer DE, Halperin JL, Hankey GJ, Berkowitz SD, Fox KAA, Patel MR. Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF trial. *J Am Coll Cardiol* 2015;**66**:2271–2281.
64. Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, Nessel CC, Berkowitz SD, Mahaffey KW, Patel MR, Sherwood MW, Becker RC, Halperin JL, Hacke W, Singer DE, Hankey GJ, Breithardt G, Fox KAA, Califf RM; ROCKET AF Investigators. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). *J Am Coll Cardiol* 2014;**63**:891–900.
65. Fox KAA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF, Hankey GJ, Mahaffey KW, Patel MR, Singer DE, Califf RM. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. *Eur Heart J* 2011;**32**:2387–2394.
66. Wang K-L, Lopes RD, Patel MR, Büller HR, Tan DS-Y, Chiang C-E, Giugliano RP. Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. *Eur Heart J* 2019;**40**:1492–1500.
67. Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, Huber K, Jansky P, Steg PG, Hanna M, Thomas L, Wallentin L, Granger CB. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes. *J Am Coll Cardiol* 2014;**63**:2141–2147.
68. Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, Granger CB, Hanna M, Held C, Husted S, Hylek EM, Jansky P, Lopes RD, Ruzyllo W, Thomas L, Wallentin L. Efficacy and safety of apixaban compared with warfarin

- according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. *Eur Heart J* 2014;**35**:1864–1872.
69. Zeitouni M, Giczewska A, Lopes RD, Wojdyla DM, Christersson C, Siegbahn A, De Caterina R, Steg PG, Granger CB, Wallentin L, Alexander JH; ARISTOTLE Investigators. Clinical and pharmacological effects of apixaban dose adjustment in the ARISTOTLE trial. *J Am Coll Cardiol* 2020;**75**:1145–1155.
  70. Alexander JH, Andersson U, Lopes RD, Hijazi Z, Hohnloser SH, Ezekowitz JA, Halvorsen S, Hanna M, Commerford P, Ruzyllo W, Huber K, Al-Khatib SM, Granger CB, Wallentin L. Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) Investigators. Apixaban 5 mg twice daily and clinical outcomes in patients with atrial fibrillation and advanced age, low body weight, or high creatinine: a secondary analysis of a randomized clinical trial. *JAMA Cardiol* 2016;**1**:673–681.
  71. Garcia DA, Fisher DA, Mulder H, Wruck L, De Caterina R, Halvorsen S, Granger CB, Held C, Wallentin L, Alexander JH, Lopes RD. Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. *Am Heart J* 2020;**221**:1–8.
  72. Dalgaard F, Mulder H, Wojdyla DM, Lopes RD, Held C, Alexander JH, De Caterina R, Washam JB, Hylek EM, Garcia DA, Gersh BJ, Wallentin L, Granger CB, Al-Khatib SM. Patients with atrial fibrillation taking nonsteroidal anti-inflammatory drugs and oral anticoagulants in the ARISTOTLE trial. *Circulation* 2020;**141**:10–20.
  73. Flaker GC, Eikelboom JW, Shestakovska O, Connolly SJ, Kaatz S, Budaj A, Husted S, Yusuf S, Lip GYH, Hart RG. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial. *Stroke* 2012;**43**:3291–3297.
  74. Ng KH, Shestakovska O, Connolly SJ, Eikelboom JW, Avezum A, Diaz R, Lanos F, Yusuf S, Hart RG. Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. *Age Ageing* 2016;**45**:77–83.
  75. Aisenberg J, Chatterjee-Murphy P, Friedman Flack K, Weitz JI, Ruff CT, Nordio F, Mercuri MF, Choi Y, Antman EM, Braunwald E, Giugliano RP. Gastrointestinal bleeding with edoxaban versus warfarin: results from the ENGAGE AF-TIMI 48 trial (effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction). *Circ Cardiovasc Qual Outcomes* 2018;**11**:e003998.
  76. Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, Deenadayalu N, Jarolim P, Betcher J, Shi M, Brown K, Patel I, Mercuri M, Antman EM. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. *Lancet* 2015;**385**:2288–2295.
  77. Brodie MM, Newman JC, Smith T, Rockey DC. Severity of gastrointestinal bleeding in patients treated with direct-acting oral anticoagulants. *Am J Med* 2018;**131**:573.e9–e15.
  78. Cangemi DJ, Krill T, Weideman R, Cipher DJ, Spechler SJ, Feagins LA. A comparison of the rate of gastrointestinal bleeding in patients taking non-vitamin K antagonist oral anticoagulants or warfarin. *Am J Gastroenterol* 2017;**112**:734–739.
  79. Abraham NS, Hartman C, Richardson P, Castillo D, Street RL, Naik AD. Risk of lower and upper gastrointestinal bleeding, transfusions, and hospitalizations with complex antithrombotic therapy in elderly patients. *Circulation* 2013;**128**:1869–1877.
  80. Lanos A, Carrera-Lasfuentes P, Arguedas Y, García S, Bujanda L, Calvet X, Ponce J, Perez-Aisa A, Castro M, Muñoz M, Sostres C, García-Rodríguez LA. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. *Clin Gastroenterol Hepatol* 2015;**13**:906–912.e2.
  81. Bo M, Falcone Y, Grisoglio E, Marchetti M, Li Puma F, Iacovino M, Brunetti E, Fonte G. Antiplatelet therapy is not a safer alternative to oral anticoagulants, even in older hospital-discharged patients with atrial fibrillation. *Geriatr Care* 2016;**2**: 6120.
  82. Masclee GMC, Valkhoff VE, Coloma PM, M de R, Romio S, Schuemie MJ, Herings R, Gini R, Mazzaglia G, Picelli G, Scotti L, Pedersen L, Kuipers EJ, J van der L, Sturkenboom MCJM. Risk of upper gastrointestinal bleeding from different drug combinations. *Gastroenterology* 2014;**147**:784–792.e9, quiz e13–14.
  83. van Rein N, Heide-Jørgensen U, Lijfering WM, Dekkers OM, Sørensen HT, Cannegieter SC. Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy. *Circulation* 2019;**139**:775–786.
  84. Chang S-H, Chou I-J, Yeh Y-H, Chiou M-J, Wen M-S, Kuo C-T, See L-C, Kuo C-F. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. *JAMA* 2017;**318**:1250–1259.
  85. Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD, Stein CM. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. *JAMA* 2018;**320**:2221–2230.
  86. Shinohara M, Wada R, Yao S, Yano K, Akitsu K, Koike H, Kinoshita T, Yuzawa H, Suzuki T, Fujino T, Ikeda T. Evaluation of oral anticoagulants in atrial fibrillation patients over 80 years of age with nonsevere frailty. *J Arrhythm* 2019;**35**:795–803.
  87. Paciaroni M, Agnelli G, Caso V, Silvestrelli G, Seiffge DJ, Engelter S, De Marchis GM, Polymeris A, Zedde ML, Yaghi S, Michel P, Eskandari A, Antonenko K, Sohn S-I, Cappellari M, Tassinari T, Tassi R, Masotti L, Katsanos AH, Giannopoulos S, Acciarresi M, Alberti A, Venti M, Mosconi MG, Vedovati MC, Pierini P, Giustozzi M, Lotti EM, Ntaios G, Kargiotis O, Monaco S, Lochner P, Bandini F, Liantinioti C, Palaiodimos L, Abdul-Rahim AH, Lees K, Mancuso M, Pantoni L, Rosa S, Bertora P, Gallizzo S, Ageno W, Toso E, Angelini F, Chiti A, Orlandi G, Denti L, Flomin Y, Marcheselli S, Mumoli N, Rimoldi A, Verrengia E, Schirinzi E, Del Sette M, Papamichalis P, Komnos A, Popovic N, Zarkov M, Rocco A, Diomedei M, Giorli E, Ciccone A, Mac Grory BC, Furie KL, Bonetti B, Saia V, Guideri F, Acampa M, Martini G, Grifoni E, Padroni M, Karagkiozi E, Perlepe K, Makaritsis K, Mannino M, Maccarrone M, Ulivi L, Giannini N, Ferrari E, Pezzini A, Doronin B, Volodina V, Baldi A, D'Amore C, Deleu D, Corea F, Putaala J, Santalucia P, Nardi K, Risitano A, Toni D, Tsvigoulis G. Causes and risk factors of cerebral ischemic events in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants for stroke prevention. *Stroke* 2019;**50**:2168–2174.
  88. Poli D, Antonucci E, Ageno W, Bertù L, Migliaccio L, Martinese L, Pilato G, Testa S, Palareti G. Oral anticoagulation in very elderly patients with atrial fibrillation: results from the prospective multicenter START2-REGISTER study. *PLoS One* 2019;**14**:e0216831.
  89. Stoll S, Macha K, Marsch A, Gerner ST, Siedler G, Fröhlich K, Volbers B, Strasser EF, Schwab S, Kallmünzer B. Ischemic stroke and dose adjustment of oral Factor Xa inhibitors in patients with atrial fibrillation. *J Neurol* 2020;**267**:2007–2012.
  90. Woo HG, Chung I, Gwak DS, Kim BK, Kim BJ, Bae H-J, Han M-K. Recurrent ischemic stroke in atrial fibrillation with non-vitamin K antagonist oral anticoagulation. *J Clin Neurosci* 2019;**64**:127–133.
  91. Barco S, Cheung YW, Eikelboom JW, Coppens M. New oral anticoagulants in elderly patients. *Best Pract Res Clin Haematol* 2013;**26**:215–224.
  92. Malik AH, Yandrapalli S, Aronow WS, Panza JA, Cooper HA. Meta-analysis of direct-acting oral anticoagulants compared with warfarin in patients >75 years of age. *Am J Cardiol* 2019;**123**:2051–2057.
  93. Bo M, Li Puma F, Badinella Martini M, Falcone Y, Iacovino M, Grisoglio E, Bonetto M, Isaia G, Ciccone G, Isaia GC, Gaita F. Health status, geriatric syndromes and prescription of oral anticoagulant therapy in elderly medical inpatients with atrial fibrillation: a prospective observational study. *Int J Cardiol* 2015;**187**:123–125.
  94. Frost CE, Song Y, Shenker A, Wang J, Barrett YC, Schuster A, Harris SI, LaCreta F. Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban. *Clin Pharmacokinet* 2015;**54**:651–662.
  95. Eikelboom JW, Quinlan DJ, Hirsh J, Connolly SJ, Weitz JI. Laboratory monitoring of non-vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation: a review. *JAMA Cardiol* 2017;**2**:566–574.
  96. Hirsh Raccach B, Rottenstreich A, Zacks N, Matok I, Danenberg HD, Pollak A, Kalish Y. Appropriateness of direct oral anticoagulant dosing and its relation to drug levels in atrial fibrillation patients. *J Thromb Thrombolysis* 2019;**47**:550–557.
  97. Testa S, Paoletti O, Legnani C, Dellanoce C, Antonucci E, Cosmi B, Pengo V, Poli D, Morandini R, Testa R, Tripodi A, Palareti G. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants. *J Thromb Haemost* 2018;**16**:842–848.
  98. Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, Yu Z, Shenker A, Barrett YC, Mosqueda-Garcia R, Lacteta F. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. *Br J Clin Pharmacol* 2013;**76**:776–786.
  99. Upreti VV, Wang J, Barrett YC, Byon W, Boyd RA, Pursley J, LaCreta FP, Frost CE. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. *Br J Clin Pharmacol* 2013;**76**:908–916.
  100. Kubitz D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. *J Clin Pharmacol* 2007;**47**:218–226.
  101. Cirincione B, Kowalski K, Nielsen J, Roy A, Thanneer N, Byon W, Boyd R, Wang X, Leil T, LaCreta F, Ueno T, Oishi M, Frost C. Population Pharmacokinetics of apixaban in subjects with nonvalvular atrial fibrillation. *CPT Pharmacometrics Syst Pharmacol* 2018;**7**:728–738.
  102. Mueck W, Stampfuss J, Kubitz D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. *Clin Pharmacokinet* 2014;**53**:1–16.